All In Biotech

Drug Trial Radar · NCT04565054

Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Adj. Dynamic Marker - Adjusted Personalized Therapy Comparing Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy in (Clinical or Genomic) High Risk, HR+/HER2- EBC

Last checked: Nov 20, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,260 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,260

Planned (sponsor's estimate)

Start

Sep 2, 2020

Primary completion

Jun 2028

Study completion Jul 2029

Sponsor

Lead sponsor
Women's Cancer Study Group GmbHAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Eli Lilly and Company; Genomic Health®, Inc.
First posted
Sep 25, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with breast cancer, who have completed first line therapy (e.g., radiotherapy, chemotherapy, surgery), and who have to be identified with having a high risk of recurrence of cancer, will be eligible for the study. This patient group is currently offered a standard of care chemotherapy plus endocrine therapy (ET). The study investigates whether the patient group with high-risk early breast cancer benefits from treatment with the medication abemaciclib in combination with ET compared to ET alone.

Conditions

  • Breast Cancer Female

Interventions

  • Abemaciclib 50 MG; 150mg 1-0-1 per osDrug

    Experimental: Abemaciclib plus ET Abemaciclib 150 mg, 2 x daily, resulting in 300 mg/day, oral, 24 months plus endocrine treatment of physician´s choice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. invasive disease-free survival (iDFS)Time frame: at end of study, 3-6 years after start of study treatment

Locations

85 sites in 3 countries. Site status is shown where the registry gives one.

  • MediOnko-Institut GbR Praxiskliik Krebsheilkunde für Frauen/Brustzentrum

    Berlin, Germany

  • Praxis für gynäkologische Onkologie im Brustzentrum City am Sankt Gertrauden KH

    Berlin, Germany

  • HELIOS Klinikum Berlin-Buch GmbH

    Berlin, Germany

  • Onkologisch-Hämatologische Schwerpunktpraxis

    Bremen, Germany

  • AGAPLESION Diakonie-Klinikum Hamburg Gyn. Studienambulanz

    Hamburg, Germany

  • Mammazentrum Hamburg MVZ GbR

    Hamburg, Germany

  • Klinikum Mittelbaden Balg

    Baden-Baden, Baden-Würtemberg, Germany

  • Praxis für interdisziplinäre Onkologie & Hämatologie

    Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • SLK Kliniken Heilbronn Klinik für Gynäkologie und Geburtshilfe

    Heilbronn, Baden-Wurttemberg, Germany

  • MVZ für Hämatologie und Onkologie

    Ravensburg, Baden-Wurttemberg, Germany

  • Universitätsklinikum Ulm Frauenheilkunde, Geburtshilfe

    Ulm, Baden-Wurttemberg, Germany

  • GRN-Klinik Weinheim Gynäkologie und Geburtshilfe

    Weinheim, Baden-Wurttemberg, Germany

  • Universitätsklinikum Tübingen Department für Frauengesundheit, Brustzentrum

    Tübingen, Baden-Wüttenburg, Germany

  • Haematologie-Onkologie im Zentrum MVZ GmbH

    Augsburg, Bavaria, Germany

  • Rotkreuzkliniken München, Interdisziplinbäres Brustzentrum

    München, Bavaria, Germany

  • Klinikum der Universität München Campus Großhadern Frauenheilunde und Geburtsklinik

    Munich, Bavaria, Germany

  • Medizinisches Zentrum für Hämatologie und Onkologie München MVZ GmbH

    Munich, Bavaria, Germany

  • Hämatologisch-Onkologische Schwerpunktpraxis Würzburg & Kitzingen

    Würzburg, Bavaria, Germany

  • Medizinische Universität Lausitz - Carl-Thiem Frauenklinik

    Cottbus, Brandenburg, Germany

  • Klinikum Ernst von Bergmann gGmbH Brustzentrum

    Potsdam, Brandenburg, Germany

  • Centrum für Hämatologie und Onkologie

    Frankfurt a.M., Hesse, Germany

  • Brustzentrum, Elisabeth-Krankenhaus gGmbH

    Kassel, Hesse, Germany

  • Gemeinschaftspraxis für Hämatologie und Onkologie

    Langen, Hesse, Germany

  • St. Josefs-Hospital Wiesbaden GmbH Ambulanz der Frauenklinik, Brustzentrum

    Wiesbaden, Hesse, Germany

  • Studien GbR Braunschweig Dr. Lorenz/Dr. Kreiss-Sender

    Braunschweig, Lower Saxony, Germany

  • MVZ II der Niels Stensen Kliniken Onkologie u. Hämatologie

    Georgsmarienhütte, Lower Saxony, Germany

  • MVZ Onkologische Kooperation Harz (GbR)

    Goslar, Lower Saxony, Germany

  • Diakovere Krankenhaus gGmbH Henriettenstift Frauenklinik

    Hanover, Lower Saxony, Germany

  • Medizinische Hochschule Hannover Frauenheilkunde

    Hanover, Lower Saxony, Germany

  • MVM Medizinische Verwaltungs und Managementgesellschaft mbH

    Leer, Lower Saxony, Germany

  • Pius-Hospital Oldenburg Hämatologie, Onkologie

    Oldenburg, Lower Saxony, Germany

  • Klinikum Südstadt Rostock Frauenklinik

    Rostock, Mecklenburg-Vorpommern, Germany

  • Stiftung Katholisches BrustCentrum Marienhospital

    Aachen, North Rhine-Westphalia, Germany

  • Uniklinik RWTH Aachen Gynäkologie und Geburtsmedizin

    Aachen, North Rhine-Westphalia, Germany

  • Evangelisches Krankenhaus Bergisch Gladbach gGmbH Brustzentrum,

    Bergisch Gladbach, North Rhine-Westphalia, Germany

  • Onkologische Schwerpunktpraxis Bielefeld

    Bielefeld, North Rhine-Westphalia, Germany

  • Gynäkologisches Zentrum Bonn PD Dr. med. Christian Kurbacher

    Bonn, North Rhine-Westphalia, Germany

  • GYNONOVA GbR Schwerpunktpraxis für gynäkologische Onkologie

    Cologne, North Rhine-Westphalia, Germany

  • St. Elisabeth-Krankenhaus GmbH, Brustzentrum - Senologie

    Cologne, North Rhine-Westphalia, Germany

  • Kliniken der Stadt Köln Krankenhaus Köln-Holweide Medizinische Klinik Brustzentrum

    Cologne, North Rhine-Westphalia, Germany

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.